On Friday, Guardant Health stock hit an important performance benchmark, with its Relative Strength (RS) Rating rising into the 80-plus percentile with an improvement to 82, an increase from 78 the day before.
When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks compares to all the other stocks in our database.
Over 100 years of market history shows that the best stocks often have an RS Rating of over 80 as they begin their biggest runs.
Looking For Winning Stocks? Try This Simple Routine
Is Guardant Health Stock A Buy?
Guardant Health stock is currently trading near its 200-day moving average. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buy zone in heavy trade.
The precision oncology company reported 0% earnings growth in its most recent report, while sales growth came in at 34%.
Guardant Health stock earns the No. 16 rank among its peers in the Medical-Services industry group. NeoGenomics and Sotera Health are also among the group's highest-rated stocks.
